Van CottEMLaposataMPrinsMH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med. 2002;126(11):1281–1295.
2.
KhorBVan CottEM. Laboratory evaluation of hypercoagulability. Clin Lab Med. 2009;29(2):339–366.
3.
WilliamsLSGargBPCohenMFleckJDBillerJ. Subtypes of ischemic stroke in children and young adults. Neurology. 1997;49(6):1541–1545.
4.
de BruijnSFAgemaWRLammersGJ. Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. Stroke. 2006;37(10):2531–2534.
5.
de AbreuTTMateusSCarreteiroCCorreiaJ. Therapeutic implications of transesophageal echocardiography after transthoracic echocardiography on acute stroke patients. Vasc Health Risk Manag. 2008;4(1):167–172.
6.
GuptaNLauCAl-DehnehA. Importance of performing transesophageal echocardiography in acute stroke patients older than fifty. Echocardiography. 2010; Jun7, PMID 20546010 (Epub ahead of print).
7.
LeungDYBlackIWCranneyGB. Selection of patients for transesophageal echocardiography after stroke and systemic embolic events. Role of transthoracic echocardiography. Stroke. 1995;26(10):1820–1824.
8.
MesseSRSilvermanIEKizerJR. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;62(7):1042–1050.
9.
O’GaraPTMesseSRTuzcuEMCathaGRingJC. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. Circulation. 2009;119(20):2743–2747.
10.
TayalAHTianMKellyKM. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology. 2008;71(21):1696–1701.
11.
BrounsRSheorajpandayRWautersADe SurgelooseDMarienPDe DeynPP. Evaluation of lactate as a marker of metabolic stress and cause of secondary damage in acute ischemic stroke or TIA. Clin Chim Acta. 2008;397(1-2):27–31.
12.
IkejiriYMoriEIshiiKNishimotoKYasudaMSasakiM. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology. 1996;47(2):583–585.
13.
KaufmannPEngelstadKWeiY. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66(3):324–330.
14.
KogaYIshibashiMUekiI. Effects of l-arginine on the acute phase of strokes in three patients with MELAS. Neurology. 2002;58(5):827–828.
15.
KogaYAkitaYNishiokaJ. l-arginine improves the symptoms of strokelike episodes in MELAS. Neurology. 2005;64(4):710–712.
